Feb 13 2026

george

A History of Russell Viper Venom

Here’s an amusing history of RVV and Dr. Russell, who named the venom. You may retrieve the article from your medical library. Thachil J. Russell viper venom: a journey from the bedside to the bench and back to the bedside. Semin Thromb Hemost. 2024;50:115-118. doi: 10.1055/s-0043-1771269.  PMID: 37506733. Abstract Russell Viper Venom (RVV) is widely […]

read more

Comments (0)

Anticoagulant Therapy

Jan 31 2026

george

What is the MRX PT DOAC Assay?

Thanks to Ali Sadeghi-Khomami, PhD, Precision BioLogic Inc., for a heads-up describing the MRX PT DOAC assay, offered by Nordic Biomarker, Umeå and Linköping, Sweden. For details about the assay, obtain this article from your medical library: Salter B, Moffat K, Carlino S, et al. Evaluation of the MRX PT DOAC assay for detection of clinically […]

read more

Comments (0)

Anticoagulant Therapy

Jan 27 2026

george

February 2026 QQ: DOACs

Our February 2026 Quick Question is a quiz that asks, “Which DOAC is a direct thrombin inhibitor?” Since 2010, DOACs have become our primary antithrombotic agents prescribed for prophylaxis or therapy. While more DOACs are on the horizon, the current anticoagulants directly inhibit either thrombin or FXa. Please make your selection in the right-hand column […]

read more

Comments (0)

Quick Question Archive

Jan 25 2026

george

World Thrombosis Day Article: Renal Vein Thrombosis

Click here for a World Thrombosis Day article about Renal Vein Thrombosis. Introduction Renal vein thrombosis is a blood clot that occurs in the veins draining blood from the kidneys. A blood clot in the renal vein will impact kidney function because it slows the flow of blood from the kidney and can reduce the […]

read more

Comments (0)

Anticoagulant Therapy

Jan 19 2026

george

The Value of Offering DOAC Measurements

Obtain this article from your medical library: Swan D, Roberts L, Thachil J. In a nutshell: testing DOAC levels-when, why and what it means? Br J Haematol. 2026. doi: 10.1111/bjh.70313. PMID: 41482473. Abstract Plasma direct oral anticoagulant (DOAC) levels are not routinely required for the majority of patients; however, they may provide valuable information in […]

read more

Comments (0)

Anticoagulant Therapy

Jan 14 2026

george

Cohort Study: Do Anticonvulsants Interfere with DOAC Therapy?

Navigate to this open-access population cohort study of the effects of anticonvulsants when used during DOAC Rx: Carlin S, Holbrook AM, Candeloro M, et al. Association of direct oral anticoagulant-anticonvulsant coprescription with clinical outcomes in older adults: a population-based cohort study. J Thromb Haemost. 2025:S1538-7836(25)00727-5. doi: 10.1016/j.jtha.2025.10.027. PMID: 41207565. Abstract Background: Anticonvulsants vary in their […]

read more

Comments (0)

Anticoagulant Therapy

Jan 9 2026

george

Anticoagulation Forum Archived Webinars

Fifth on our alphabetical Hemostasis Agencies list is the Anticoagulation Forum. The forum offers a lengthy list of archived educational webinars that describe a number of antithrombotic therapy issues. Click here for the forum’s webinar selection.

read more

Comments (0)

Anticoagulant Therapy

Dec 29 2025

george

Andexanet Alfa Withdrawn from the US Market

Thanks for the heads-up from Dr. Paul Riley, who commented on our December 27, 2025, post, Clinical Research Study: Andexanet Alfa for Enoxaparin Reversal. Here is the press release from AstraZeneca announcing the withdrawal of andexanet alfa from the US market.

read more

Comments (0)

Blog

Dec 27 2025

george

Clinical Research Study: Andexanet Alfa for Enoxaparin Reversal

Navigate to this open-access article describing andexanet alfa reversal of LMWH: van Haaps TF, Benz AP, Xu L, Middeldorp S, Eikelboom JW, et al. Andexanet alfa for the reversal of the low-molecular-weight heparin enoxaparin. Res Pract Thromb Haemost. 2025;9:103191. doi: 10.1016/j.rpth.2025.103191. PMID: 41141842; PMCID: PMC12552982. Abstract Background Andexanet alfa (andexanet) is the only approved reversal […]

read more

Comments (1)

Anticoagulant Therapy

Dec 26 2025

george

August 2025 CAP Today: D-dimer Reporting and INR Are Variables That Matter

In follow-up to their July 2025 CAP Today article, A Deep Dive into Key Hemostasis Testing Variables, Drs. Andrew Goodwin and Eric Salazar present external quality improvement data on the PT–INR, D-dimer, and VET in their August 2025 article, D-dimer Reporting and INR Are Variables That Matter. Their article in particular examines the confusion over […]

read more

Comments (0)

Anticoagulant Therapy